The PTH1R thus has an intrinsic capacity for dual ligand recognition, which opens possibilities for exploring new modes of therapeutic development for diseases such as osteoporosis and hypoparathyroidism (Jüppner et al., 1991; Gardella and Jüppner, 2000; Bone et al., 2004; Rubin et al., 2016; Winer et al., 1996; Winer et al., 2018). The gene discussed is PTH1R; the disease is hypoparathyroidism.